Literature DB >> 3937268

The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants.

B M Alving, P E Baldwin, R L Richards, B J Jackson.   

Abstract

A simple sensitive method for verification of lupus anticoagulants utilizing dilution of phospholipid in the activated partial thromboplastin time (APTT) system is described. Patient plasma, mixed with an equal volume of normal plasma, is activated with micronized silica. To this mixture are added different dilutions of Thrombofax and then calcium chloride. Clotting times are plotted linearly against the logarithm of the phospholipid dilutions and slopes are calculated by regression analysis. In this assay the mean negative slope of 19 plasmas that contained anti-phospholipid activity was five times greater than those of normal plasma or those obtained from patients having single or multiple coagulation factor deficiencies such as those induced by warfarin. The assay can be modified to test heparinized plasmas. Thus, it is a sensitive means by which to verify the presence of lupus anticoagulants in patients who have congenital or acquired factor deficiencies or who are receiving anticoagulant therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3937268

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Lupus anticoagulant activities of murine monoclonal antibodies to liposomal phosphatidylinositol phosphate.

Authors:  B M Alving; B Banerji; W E Fogler; C R Alving
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

2.  Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus.

Authors:  D Ferro; M Saliola; C Quintarelli; G Valesini; S Basili; A M Grandilli; M S Bonavita; F Violi
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

Review 3.  Detection of lupus anticoagulants.

Authors:  M H Horellou; M M Samama
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.

Authors:  F Violi; D Ferro; G Valesini; C Quintarelli; M Saliola; M A Grandilli; F Balsano
Journal:  BMJ       Date:  1990-04-28

5.  Prevalence and significance of anticardiolipin antibodies in Crohn's disease.

Authors:  P Chamouard; L Grunebaum; M L Wiesel; J M Freyssinet; B Duclos; J P Cazenave; R Baumann
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

6.  Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

Authors:  R H Derksen; P Hasselaar; L Blokzijl; F H Gmelig Meyling; P G De Groot
Journal:  Ann Rheum Dis       Date:  1988-05       Impact factor: 19.103

Review 7.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

8.  A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.

Authors:  Tom R Gaunt; Gordon D O Lowe; Debbie A Lawlor; Juan-Pablo Casas; Ian N M Day
Journal:  Eur J Hum Genet       Date:  2012-11-28       Impact factor: 4.246

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.